Home Talks and Publications

I recently gave a talk on educating the next generation of biotechnology managers and founders at a biotechnology education workshop. My sense is that the traditional education paths are not ideal ways to prepare individuals to manage or start biotechnology companies, and I describe cases from Best Practices in Biotechnology Education and courses I have been involved with to illustrate how educational programs can better prepare students for these roles.

I’ve attached a copy of my presentation below.

I will be giving a talk on Educating the Next Generation of Biotechnology Founders and Managers at Pittcon in Orlando on March 1st.

The talk will be based on my observations in writing  Building Biotechnology and editing Best Practices in Biotechnology Education, in addition to the teaching I’ve done on the topic. I’ll be posting my slides after the event, but for a preview you can see my recent editorial on continuing education in biotechnology in the Journal of Commercial Biotechnology.

Hope to meet some readers while I’m down there…

I’m giving a talk at Pittcon on biotechnology training this spring. As many readers know, I have been very active in biotechnology education through my books and the classes I teach. So, I’ve got a strong sense of the supply-side of biotechnology education and training, and the academic side of biotechnology education, but would like some more perspective on the industry side of biotechnology education and training.

So, I’d like to post an open question:

How do you train your new biotechnology employees?

I want to learn more about the training systems used to bring new hires, with either scientific or business backgrounds, up to speed on the business of biotechnology. What are the methods and tools you use? You may post your response in the comments below, or if you’d rather be off the record, feel free to contact me directly.

The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 16, Issue 1


Time for a new business model?PDF
Yali Friedman


Why data exclusivity is the new patent protectionPDF
Peter J Pitts
Follow-on biologic drug competition – No need for new marketing exclusivitiesPDF
Michael S Wroblewski, Elizabeth A Jex


Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumbPDF
Nigel Borshell, Adrian Dawkes
Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firmsPDF
Mark J Ahn, Michael Meeks, Sally Davenport, Rebecca Bednarek
Intellectual property landscape and patenting opportunity in biofuelsPDF
Ramasamy Mannan
Challenges and opportunities in the licensing of renewable technologiesPDF
Meredith Lloyd-Evans, Mike Gilbert, Ilian P Iliev
Ethiopia: Biotechnology for developmentPDF
Desta Berhe Sbhatu
Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economyPDF
Olivia Harvey

Legal and Regulatory Updates

Using IP audits to optimize IP assetsPDF
James G Cullem

Book Reviews

Book Review: Health-care investing: Profiting from the new world of pharma, biotech and health-care servicesPDF
Frank LaSaracina
Book Review: Aging, Biotechnology, and the FuturePDF
Harley King

I am honored to have been selected for the 2009 Kyoto Prize Journalism Fellowship, offered by Point Loma Nazarene University.

This fellowship will allow me to attend the Kyoto Prize Ceremony, laureate lectures and workshops, and associated functions. The Kyoto Prize is one of the world’s most prestigious awards given to those who have made outstanding lifetime achievements in technology, science, or the arts. This year’s laureates are:

Dr. Isamu Akasaki, Blue LED pioneer

Drs. Peter and Rosemary Grant, Evolutionary Biologists

Pierre Boulez, World-renowned composer, conductor

I am honored to have the opportunity to attend this prestigious event and to learn more about innovation in diverse disciplines.

The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 15, Issue 4


Intellectual property and biotechnology innovation: To protect or not protect?PDF
Yali Friedman


The correlation between medical tourism and biotechnologyPDF
David G Vequist IV, Erika Valdez
The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interviewPDF
William Bains


Innovate America: The Technology Innovation Program at NISTPDF
Andrew S Klein, Mrunal S Chapekar
Valuation of complex license contractsPDF
Ralph Villiger, Boris Bogdan
How can pharmaceutical and biotechnology companies maintain a high profitability?PDF
Klaus J Nickisch, Joachim M Greuel, Kerstin M Bode-Greuel
Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industryPDF
J Leslie Glick
Building biotechnology teams: Personality does matterPDF
Anne S York, Kim A McCarthy, Todd C Darnold
Beacon Sciences: Commercialisation from biothreat detection to beauty enhancementPDF
Rob Hanes, Damon Borich

Legal and Regulatory Updates

Legal and Regulatory UpdatePDF
Gerry Kamstra, John Wilkinson

Book Reviews

Book Review: Genomics & society: Legal, ethical and social dimensionsPDF
Dominic Clark
Book Review: Commercialization of innovative technologies: Bringing good ideas to the marketplacePDF
Arlen D Meyers
Book Review: Biotech funding trends: Insights from entrepreneurs and investorsPDF
J Leslie Glick

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic hardships, given the direct health and indirect economic benefits of biotechnology research, will governments sustain, increase, or decrease their R&D budgets?

The impact of the global financial crisis on biotechnology development

The July 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 15, Issue 3


The impact of the global financial crisis on biotechnology developmentPDF
Yali Friedman


Can genetic engineering prevent food-poisoning?PDF
Henry Miller


Bottom line compliance for biotechnology: Six secretsPDF
John Avellanet
Maturation of the biotechnology industry changes job opportunities for scientistsPDF
Helen Liu, Molly B Schmid
Biotechnology business models: An Indian perspectivePDF
Viren Konde
Tracking progress: Two approaches to biotechnology development – Cases from Central EuropePDF
Tomasz Mroczkowski, Heather Elms
Umbilical cord blood banks: Modern day alchemyPDF
Helen Smith
China 10-Point Patent Checklist: Integrating patents into an overall business strategy for a Western manufacturing entity in ChinaPDF
Catherine Sun, Sharon R Barner, Harold C Wegner

From the Classroom

Bioscience enterprise: Postgraduate education at Cambridge and AucklandPDF
Linda Allan, Joerg Kistler, Chris Lowe, Wendell Dunn, Claire McGowan, Geoff Whitcher

Legal and Regulatory Updates

Legal and regulatory updatePDF
John Wilkinson

Book Reviews

Book Review: Spin-outs: Creating businesses from university intellectual propertyPDF
Arlen D Meyers
Book Review: Venture capital and the European biotechnology industryPDF
Leonard Lerer